Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab for C. Difficile Relapse Prevention
NCT03937999Phase 4Terminated
- Sponsor
- Montefiore Medical Center
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bezlotoxumab in Clostridioides difficile infection (CDI) (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Recurrence of C.Difficile Infection at 4 weeks. Started Aug 2019; status: terminated.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03937999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937999.